US health insurers slide after CMS proposes just 0.09% Medicare Advantage rate increase for 2027

Shares of U.S. health insurers tumbled Tuesday after the Centers for Medicare and Medicaid Services (CMS) proposed an average payment increase of just 0.09% for Medicare Advantage plans in 2027—well below what many analysts and investors had expected. The proposal immediately raised concerns that insurers may have to scale back benefits, raise out-of-pocket costs, reduce plan availability, or exit certain markets to protect margins as medical cost trends remain high.

In premarket trading, major companies tied closely to Medicare Advantage were hit hard, including UnitedHealth, Humana, and CVS. The sharp move reflects how sensitive the sector is to government reimbursement policy: Medicare Advantage is a large and growing part of many insurers’ business models, and even modest changes in projected rates can significantly affect profitability expectations over multi-year planning cycles.

Why 0.09% is a big deal

The headline number matters because it is being compared to medical cost inflation and utilization trends. If payments barely rise while costs climb, insurers face an arithmetic problem: they must either accept lower margins or take actions that shift costs, limit benefits, or constrain membership growth. Analysts noted that the proposed increase implies only about $700 million in additional payments—small relative to the size of the program—and far from expectations some market participants had been using in forecasts.

The implications extend beyond Wall Street. Medicare Advantage plans compete partly on extra benefits—such as dental, vision, fitness programs, and lower premiums—options that can become harder to maintain when reimbursement is pressured. If plans pull back those extras, the change can be felt directly by enrollees shopping during open enrollment, especially in counties where competition is thin.

What insurers may do next

• Reprice 2027 plan bids with tighter benefit packages or narrower provider networks.
• Reduce marketing and slow expansion in counties with weaker economics.
• Exit select markets or product segments where reimbursement and costs are most mismatched.

The proposal is not necessarily final, and CMS rulemaking can evolve after industry feedback. Still, the market reaction signals that investors expect meaningful downstream effects. The key question for the coming months is whether CMS adjusts the rate outlook—and, if not, how quickly insurers translate reimbursement pressure into plan design changes that beneficiaries will notice.